2014 Abstracts of SAKK and Collaborating Groups

ESMO 2014 congress Madrid

Oral presentations

Pless M. et al. Final results of the SAKK 16/00 trial: a randomized phase III trial comparing neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small cell lung cancer (NSCLC).

Stahel RA. et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy: final results of the randomized multicenter phase II trial SAKK17/04.

Poster discussion


Poster

Templeton A. et al. Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks–a non-inferiority phase III trial: SAKK 96/12 - REDUSE.

Rothschild S. et al. Prospective evaluation of circulating VEGF in patients with advanced non-small cell lung cancer treated with bevacizumab, pemetrexed and cisplatin in the trial SAKK19/09.

Matter-Walstra K. et al. Health economic analysis of the randomized multicenter phase II trial SAKK 77/08: sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC).

ASTRO 56th Annual Meeting

Poster


ASCO Annual Meeting 2014

Poster

Templeton A. et al. Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks – a non-inferiority phase III trial (SAKK 96/12, REDUSE).
Koeberle D. et al. Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).

Oral presentation

Sargent DJ. et al. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database (SAKK 60/00).

Poster discussion

Von Moos R. et al. Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08.

Rochlitz C. et al. SAKK 24/09: Safety and tolerability of bevacizumab plus Paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer. A multicenter, randomized phase III trial.

ELCC 2014 European Lung Cancer Conference Geneva

Poster

Gautschi O. et al. Thymidylate synthetase (TYMS) expression is not predictive in patients with metastatic NSCLC treated with pemetrexed, cisplatin and bevacizumab in the SAKK19/09 trial.